« Back
Home /
AER-271

AER-271

Manufacturer	ChemScene
Category	Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Amount	5mg
Item no.	CS-0087000-5mg
eClass 6.1	32169090
eClass 9.0	32169090
Available
CAS	634913-39-6
Purity	>98%
MWt	463.65
Formula	C15H9ClF6NO5P
Solubility	DMSO : 125 mg/mL (269.60 mM; Need ultrasonic)
Clinical Information	No Development Reported
Pathway	Others
Target	Others
Biological Activity	AER-271, a phosphonate prodrug derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor for the research of acute ischemic stroke^[1]. IC50 & Target: Aquaporin-4 (AQP4)^[1] In Vivo: AER-271 is converted in vivo to AER-270 by endogenous phosphatases. AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest^[1]. AER-271 reduces cerebral edema and improves neurological outcomes in rodent ischemic stroke models. Mice treated with AER-271 (5?mg/kg; i.p. injection) show improved outcomes and reduced cerebral edema in a model of ischemic stroke^[2].
Research Area	Neurological Disease; Cardiovascular Disease

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5mg

available

Delivery expected until 6/6/2024